What's Happening?
Roche, in partnership with Klinrisk, has received a CE-mark in the EU for an AI-based tool designed to predict renal function decline in patients with chronic kidney disease (CKD). This algorithm will be integrated into Roche's navify library, which includes various digital health technologies aimed at enhancing clinical decision-making. The Kidney Klinrisk Algorithm is the first AI-based tool to receive a CE-mark for assessing progressive kidney function decline. It complements the already CE-marked Kidney KFRE Algorithm, which manages later stages of CKD. The tool is intended for early risk assessment in adults diagnosed with CKD and those with diabetes or hypertension at elevated risk for kidney function decline.
Why It's Important?
The approval of this AI-based algorithm is a significant advancement in the management of CKD, a condition affecting a substantial portion of the global population. By enabling early risk assessment, the algorithm could facilitate earlier intervention with medications that slow CKD progression, potentially improving patient outcomes and reducing healthcare costs. This development highlights the growing role of AI in healthcare, particularly in enhancing diagnostic accuracy and personalizing treatment plans.
What's Next?
Following its approval in the EU, the Kidney Klinrisk Algorithm is expected to be launched in the UK, with plans for further expansion into the US, the Middle East, and Asian markets. This expansion could lead to broader adoption of the tool, potentially transforming CKD management practices and improving patient care on a global scale.
